Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Working out at the airport? Some fliers can already smell the sweat. - 24 Sound blocking Earphones for Prevalent Sound and Solace
- 3More parents refusing this shot that prevents serious bleeding at birth
- 4Savvy Watches: Which One Is Appropriate for You?
- 5Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- Ten Awesome Authentic Realities That Will Leave You Interested
- Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- Israel faces widespread condemnation as NGO ban comes into effect
- South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- Most loved Fish Dish: What's Your Sea Pleasure?
- Discovering a sense of harmony: Individual Accounts of Reflection and Care
